Ipamorelin research focuses on one of the most selective growth hormone secretagogues studied to date. This pentapeptide belongs to the growth hormone releasing peptide (GHRP) family. Investigators study it for its ability to stimulate growth hormone release with a clean signalling profile. Below is a factual overview of what current literature describes about this compound.
What Is Ipamorelin?
Ipamorelin is a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor (GHS-R1a). By binding this receptor in the pituitary gland, it prompts the release of stored growth hormone. Researchers classify it as a third-generation GHRP because of its refined receptor selectivity compared to earlier compounds.
How Ipamorelin Works in Research Models
Ipamorelin mimics the action of ghrelin, the body’s natural hunger and growth-hormone-signalling peptide. When it activates GHS-R1a, calcium influx in pituitary somatotroph cells increases. This triggers a pulse of growth hormone into circulation. Studies note that the response is dose-dependent and mirrors the body’s natural pulsatile secretion pattern rather than producing a constant elevation.
Selectivity: What Sets Ipamorelin Apart
The defining feature in the literature is selectivity. Earlier secretagogues such as GHRP-6 and GHRP-2 also raise cortisol, prolactin, and appetite alongside growth hormone. Research on Ipamorelin describes minimal impact on cortisol and prolactin at effective doses. This clean profile makes it a frequent reference compound in studies isolating growth hormone pathways from other hormonal noise. For a related comparison, see our GHRP-2 research listing.
Ipamorelin and CJC-1295 in Combined Research
Ipamorelin is frequently studied alongside CJC-1295, a growth hormone releasing hormone (GHRH) analogue. The two act on different receptors. CJC-1295 increases the amount of growth hormone available for release, while Ipamorelin triggers the release itself. Investigators examine this pairing because the mechanisms are complementary rather than overlapping. Combined preparations such as the CJC-1295 no DAC + Ipamorelin blend appear often in this line of study.
Half-Life and Stability Considerations
Ipamorelin has a relatively short half-life, generally reported around two hours in research contexts. This short duration produces a discrete growth hormone pulse before levels return to baseline. Lyophilised Ipamorelin is stable when stored cold and reconstituted with bacteriostatic water for laboratory handling. Its stability and predictable kinetics contribute to its popularity as a research standard.
Why Ipamorelin Research Continues
Ipamorelin research remains a benchmark within growth hormone axis science. Its selectivity, predictable pulsatile response, and favourable stability make it useful for isolating specific signalling questions. Scientists continue to reference it when designing experiments on somatotroph function, receptor pharmacology, and GHRP structure-activity relationships. Peer-reviewed literature indexed on PubMed continues to inform ongoing Ipamorelin research.
All products sold at EhBuddy Peptides are for laboratory and scientific research purposes only and are not intended for human or veterinary administration. EhBuddy Peptides ships all orders from within Canada.
